

REFERENCES

1. WHO. Cancer; 2006 25 June 2007 Contract No.: Document Number|.
2. American Cancer Society. Report sees 7.6 million global 2007 cancer deaths; 2007 7 August 2008 Contract No.: Document Number|.
3. Kinzler KW, Vogelstein, B. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill, Medical Pub. Division; 2002.
4. Croce CM. Oncogenes and cancer. N Engl J Med. 2008 Jan 31;358(5):502-11.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001 Nov 1;414(6859):105-11.
6. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28.
7. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001 May 17;411(6835):349-54.
8. Marx J. Cancer research. Mutant stem cells may seed cancer. Science. 2003 Sep 5;301(5638):1308-10.
9. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3547-9.
10. Sangeetha P, Das UN, Koratkar R, Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic Biol Med. 1990;8(1):15-9.
11. Faure H, Coudray C, Mousseau M, Ducros V, Douki T, Bianchini F, et al. 5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant

- vitamins in adriamycin-treated patients. *Free Radic Biol Med.* 1996;20(7):979-83.
12. Hunnisett A, Davies S, McLaren-Howard J, Gravett P, Finn M, Gueret-Wardle D. Lipoperoxides as an index of free radical activity in bone marrow transplant recipients. Preliminary observations. *Biol Trace Elem Res.* 1995 Jan-Mar;47(1-3):125-32.
13. Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. *Cancer Treat Rev.* 1997 Jul;23(4):209-40.
14. Dechsupa S, Kothan S, Vergote J, Leger G, Martineau A, Berangeo S, et al. Quercetin, Siamois 1 and Siamois 2 induce apoptosis in human breast cancer MDA-mB-435 cells xenograft in vivo. *Cancer Biol Ther.* 2007 Jan;6(1):56-61.
15. Kothan S, Dechsupa S, Leger G, Moretti JL, Vergote J, Mankhetkorn S. Spontaneous mitochondrial membrane potential change during apoptotic induction by quercetin in K562 and K562/adr cells. *Can J Physiol Pharmacol.* 2004 Dec;82(12):1084-90.
16. Choiprasert W. Structure activity relationship studies on the flavonoid binding on albumin and multidrug resistance reversing actions. Chiang Mai: Chiang Mai University; 2009.
17. Lozano C, Torres JL, Julia L, Jimenez A, Centelles JJ, Cascante M. Effect of new antioxidant cysteinyl-flavanol conjugates on skin cancer cells. *FEBS Lett.* 2005 Aug 15;579(20):4219-25.
18. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, et al. The antitumor activities of flavonoids. *In Vivo.* 2005 Sep-Oct;19(5):895-909.

19. Harrison DE, Lerner CP. Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. *Blood*. 1991 Sep 1;78(5):1237-40.
20. Bouwens L, De Blay E. Islet morphogenesis and stem cell markers in rat pancreas. *J Histochem Cytochem*. 1996 Sep;44(9):947-51.
21. Domen J, Gandy KL, Weissman IL. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. *Blood*. 1998 Apr 1;91(7):2272-82.
22. Feuerhake F, Sigg W, Hofter EA, Dimpfl T, Welsch U. Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium. *Cell Tissue Res*. 2000 Jan;299(1):47-58.
23. Peters R, Leyvraz S, Perey L. Apoptotic regulation in primitive hematopoietic precursors. *Blood*. 1998 Sep 15;92(6):2041-52.
24. Terskikh AV, Easterday MC, Li L, Hood L, Kornblum HI, Geschwind DH, et al. From hematopoiesis to neurogenesis: evidence of overlapping genetic programs. *Proc Natl Acad Sci U S A*. 2001 Jul 3;98(14):7934-9.
25. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat Med*. 2001 Sep;7(9):1028-34.
26. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. *Trends Cell Biol*. 2000 Sep;10(9):369-77.
27. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria as targets for cancer chemotherapy. *Semin Cancer Biol*. 2009 Feb;19(1):57-66.

28. Igaki T, Suzuki Y, Tokushige N, Aonuma H, Takahashi R, Miura M. Evolution of mitochondrial cell death pathway: Proapoptotic role of HtrA2/Omi in *Drosophila*. *Biochem Biophys Res Commun*. 2007 May 18;356(4):993-7.
29. Reungpatthanaphong P, Dechsupa S, Meesungnoen J, Loetchutinat C, Mankhetkorn S. Rhodamine B as a mitochondrial probe for measurement and monitoring of mitochondrial membrane potential in drug-sensitive and -resistant cells. *J Biochem Biophys Methods*. 2003 Jul 31;57(1):1-16.
30. Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Vinodhkumar R, Devaki T. Stabilization of pulmonary mitochondrial enzyme system by capsaicin during benzo(a)pyrene induced experimental lung cancer. *Biomed Pharmacother*. 2008 Jul-Aug;62(6):390-4.
31. Laconi E. The evolving concept of tumor microenvironments. *Bioessays*. 2007 Aug;29(8):738-44.
32. Gillies RJ, Gatenby RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. *Cancer Metastasis Rev*. 2007 Jun;26(2):311-7.
33. Swietach P, Zaniboni M, Stewart AK, Rossini A, Spitzer KW, Vaughan-Jones RD. Modelling intracellular H(+) ion diffusion. *Prog Biophys Mol Biol*. 2003 Oct;83(2):69-100.
34. Zaniboni M, Swietach P, Rossini A, Yamamoto T, Spitzer KW, Vaughan-Jones RD. Intracellular proton mobility and buffering power in cardiac ventricular myocytes from rat, rabbit, and guinea pig. *Am J Physiol Heart Circ Physiol*. 2003 Sep;285(3):H1236-46.
35. Spitzer KW, Skolnick RL, Peercy BE, Keener JP, Vaughan-Jones RD. Facilitation of intracellular H(+) ion mobility by CO(2)/HCO(3)(-) in rabbit ventricular

- myocytes is regulated by carbonic anhydrase. *J Physiol.* 2002 May 15;541(Pt 1):159-67.
36. Stewart AK, Boyd CA, Vaughan-Jones RD. A novel role for carbonic anhydrase: cytoplasmic pH gradient dissipation in mouse small intestinal enterocytes. *J Physiol.* 1999 Apr 1;516 (Pt 1):209-17.
37. Curtin JF, Donovan M, Cotter TG. Regulation and measurement of oxidative stress in apoptosis. *J Immunol Methods.* 2002 Jul 1;265(1-2):49-72.
38. Halliwell B, Gutteridge, J.M.C. *Free Radicals in Biology and Medicine.* 3rd, editor. Oxford: Oxford University Press; 1999.
39. Sun AY, Chen YM. Oxidative stress and neurodegenerative disorders. *J Biomed Sci.* 1998 Nov-Dec;5(6):401-14.
40. Viidas U, Ahlmen, J., Hedner, T., Cajdahl, K., Larsson, A., Pettersson, A., Stroömbom, U. Nitric oxide and blood pressure in normotensive patients on chronic hemodialysis. *Dial Transplant.* 1998;27:714-24.
41. Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. *Cancer Res.* 1994 May 1;54(9):2462-7.
42. Rosen GM, Pou S, Ramos CL, Cohen MS, Britigan BE. Free radicals and phagocytic cells. *FASEB J.* 1995 Feb;9(2):200-9.
43. Kannan K, Jain SK. Oxidative stress and apoptosis. *Pathophysiology.* 2000 Sep;7(3):153-63.
44. Maulik N, Das DK. Redox signaling in vascular angiogenesis. *Free Radic Biol Med.* 2002 Oct 15;33(8):1047-60.
45. Huang RP, Wu JX, Fan Y, Adamson ED. UV activates growth factor receptors via reactive oxygen intermediates. *J Cell Biol.* 1996 Apr;133(1):211-20.

46. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. *J Cell Physiol.* 2002 Jul;192(1):1-15.
47. Ravid T, Sweeney C, Gee P, Carraway KL, 3rd, Goldkorn T. Epidermal growth factor receptor activation under oxidative stress fails to promote c-Cbl mediated down-regulation. *J Biol Chem.* 2002 Aug 23;277(34):31214-9.
48. Nakamura T, Sakamoto K. Reactive oxygen species up-regulates cyclooxygenase-2, p53, and Bax mRNA expression in bovine luteal cells. *Biochem Biophys Res Commun.* 2001 Jun 1;284(1):203-10.
49. Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A, et al. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. *EMBO J.* 2002 Nov 1;21(21):5635-44.
50. Li N, Karin M. Is NF-kappaB the sensor of oxidative stress? *FASEB J.* 1999 Jul;13(10):1137-43.
51. Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. *J Clin Invest.* 2001 Feb;107(3):247-54.
52. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. *Cancer Chemother Pharmacol.* 2004 Mar;53(3):209-19.
53. Harborne JB, Williams CA. Advances in flavonoid research since 1992. *Phytochemistry.* 2000 Nov;55(6):481-504.
54. Robbins RJ. Phenolic acids in foods: an overview of analytical methodology. *J Agric Food Chem.* 2003 May 7;51(10):2866-87.
55. Pietta PG. Flavonoids as antioxidants. *J Nat Prod.* 2000 Jul;63(7):1035-42.
56. Xie DY, Dixon RA. Proanthocyanidin biosynthesis--still more questions than answers? *Phytochemistry.* 2005 Sep;66(18):2127-44.

57. Afanas'ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovitch AI. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. *Biochem Pharmacol.* 1989 Jun 1;38(11):1763-9.
58. Bors W, Heller W, Michel C, Saran M. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. *Methods Enzymol.* 1990;186:343-55.
59. Fiorani M, De Sanctis R, De Bellis R, Dacha M. Intracellular flavonoids as electron donors for extracellular ferricyanide reduction in human erythrocytes. *Free Radic Biol Med.* 2002 Jan 1;32(1):64-72.
60. Miller NJ, Paganga, G. Antioxidant properties of phenolic compounds. *Trends Plant Sci.* 1997;2:152-9.
61. Rifici VA, Stephan EM, Schneider SH, Khachadurian AK. Red wine inhibits the cell-mediated oxidation of LDL and HDL. *J Am Coll Nutr.* 1999 Apr;18(2):137-43.
62. Foti P, Erba D, Riso P, Spadafranca A, Criscuoli F, Testolin G. Comparison between daidzein and genistein antioxidant activity in primary and cancer lymphocytes. *Arch Biochem Biophys.* 2005 Jan 15;433(2):421-7.
63. Jeyabal PV, Syed MB, Venkataraman M, Sambandham JK, Sakthisekaran D. Apigenin inhibits oxidative stress-induced macromolecular damage in N-nitrosodiethylamine (NDEA)-induced hepatocellular carcinogenesis in Wistar albino rats. *Mol Carcinog.* 2005 Sep;44(1):11-20.
64. Mei Y, Wei D, Liu J. Reversal of multidrug resistance in KB cells with tea polyphenol antioxidant capacity. *Cancer Biol Ther.* 2005 Apr;4(4):468-73.

65. Labieniec M, Gabryelak T, Falcioni G. Antioxidant and pro-oxidant effects of tannins in digestive cells of the freshwater mussel *Unio tumidus*. *Mutat Res.* 2003 Aug 5;539(1-2):19-28.
66. Galati G, O'Brien PJ. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. *Free Radic Biol Med.* 2004 Aug 1;37(3):287-303.
67. Crack PJ, Taylor JM. Reactive oxygen species and the modulation of stroke. *Free Radic Biol Med.* 2005 Jun 1;38(11):1433-44.
68. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. *Antioxid Redox Signal.* 2005 Mar-Apr;7(3-4):395-403.
69. Fito M, Covas MI, Lamuela-Raventos RM, Vila J, Torrents L, de la Torre C, et al. Protective effect of olive oil and its phenolic compounds against low density lipoprotein oxidation. *Lipids.* 2000 Jun;35(6):633-8.
70. Vieira O, Escargueil-Blanc I, Meilhac O, Basile JP, Laranjinha J, Almeida L, et al. Effect of dietary phenolic compounds on apoptosis of human cultured endothelial cells induced by oxidized LDL. *Br J Pharmacol.* 1998 Feb;123(3):565-73.
71. Park C, So HS, Shin CH, Baek SH, Moon BS, Shin SH, et al. Quercetin protects the hydrogen peroxide-induced apoptosis via inhibition of mitochondrial dysfunction in H9c2 cardiomyoblast cells. *Biochem Pharmacol.* 2003 Oct 1;66(7):1287-95.
72. Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB. The relative antioxidant activities of plant-derived polyphenolic flavonoids. *Free Radic Res.* 1995 Apr;22(4):375-83.

73. Satyanarayana PS, Singh D, Chopra K. Quercetin, a bioflavonoid, protects against oxidative stress-related renal dysfunction by cyclosporine in rats. *Methods Find Exp Clin Pharmacol*. 2001 May;23(4):175-81.
74. Fadeel B, Gleiss B, Hogstrand K, Chandra J, Wiedmer T, Sims PJ, et al. Phosphatidylserine exposure during apoptosis is a cell-type-specific event and does not correlate with plasma membrane phospholipid scramblase expression. *Biochem Biophys Res Commun*. 1999 Dec 20;266(2):504-11.
75. Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. *Cardiovasc Res*. 2000 Feb;45(3):528-37.
76. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. *Nat Rev Mol Cell Biol*. 2001 Aug;2(8):589-98.
77. Denault JB, Salvesen GS. Caspases: keys in the ignition of cell death. *Chem Rev*. 2002 Dec;102(12):4489-500.
78. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. *EMBO J*. 1998 Mar 16;17(6):1675-87.
79. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. *J Cell Biol*. 1999 Jan 25;144(2):281-92.
80. Salvesen GS, Renatus M. Apoptosome: the seven-spoked death machine. *Dev Cell*. 2002 Mar;2(3):256-7.
81. Hsieh TC, Wu JM. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. *Exp Cell Res*. 1999 May 25;249(1):109-15.

82. Romero I, Paez A, Ferruelo A, Lujan M, Berenguer A. Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP cells. *BJU Int.* 2002 Jun;89(9):950-4.
83. Wenzel U, Kuntz S, Brendel MD, Daniel H. Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. *Cancer Res.* 2000 Jul 15;60(14):3823-31.
84. Murphy AN. Potential mechanism of mitochondrial cytochrome-c release during apoptosis. *Drug Dev Res.* 1999;46:18-25.
85. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. *Eur J Cancer.* 1999 Oct;35(10):1517-25.
86. Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A. Induction of apoptosis by quercetin: involvement of heat shock protein. *Cancer Res.* 1994 Sep 15;54(18):4952-7.
87. Liu MJ, Wang Z, Li HX, Wu RC, Liu YZ, Wu QY. Mitochondrial dysfunction as an early event in the process of apoptosis induced by woodfordin I in human leukemia K562 cells. *Toxicol Appl Pharmacol.* 2004 Jan 15;194(2):141-55.
88. Zhao Y, Yang LF, Ye M, Gu HH, Cao Y. Induction of apoptosis by epigallocatechin-3-gallate via mitochondrial signal transduction pathway. *Prev Med.* 2004 Dec;39(6):1172-9.
89. Kampa M, Alexaki VI, Notas G, Nifli AP, Nistikaki A, Hatzoglou A, et al. Antiproliferative and apoptotic effects of selective phenolic acids on T47D

human breast cancer cells: potential mechanisms of action. *Breast Cancer Res.* 2004;6(2):R63-74.

90. Han DH, Jeong JH, Kim JH. Anti-proliferative and apoptosis induction activity of green tea polyphenols on human promyelocytic leukemia HL-60 cells. *Anticancer Res.* 2009 Apr;29(4):1417-21.
91. Kang JW, Kim JH, Song K, Kim SH, Yoon JH, Kim KS. Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3-dependent apoptosis in oral cavity cancer cells. *Phytother Res.* 2009 Jul 7.
92. Sakao K, Fujii M, Hou DX. Acetyl derivate of quercetin increases the sensitivity of human leukemia cells toward apoptosis. *Biofactors.* 2009 Jun 29.
93. Wu PP, Kuo SC, Huang WW, Yang JS, Lai KC, Chen HJ, et al. (-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway. *Anticancer Res.* 2009 Apr;29(4):1435-42.
94. Jin CY, Park C, Kim GY, Lee SJ, Kim WJ, Choi YH. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. *Chem Biol Interact.* 2009 Jul 15;180(2):143-50.
95. Manson MM. Cancer prevention -- the potential for diet to modulate molecular signalling. *Trends Mol Med.* 2003 Jan;9(1):11-8.
96. Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M, Pereira-Wilson C. Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. *Cancer Lett.* 2009 Aug 28;281(2):162-70.

97. Yin F, Giuliano AE, Van Herle AJ. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). *Anticancer Res.* 1999 Sep-Oct;19(5B):4297-303.
98. Jain RK. Delivery of molecular and cellular medicine to solid tumors. *Adv Drug Deliv Rev.* 2001 Mar 1;46(1-3):149-68.
99. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. *Proc Natl Acad Sci U S A.* 2001 Apr 10;98(8):4628-33.
100. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. *Nat Med.* 2001 Sep;7(9):987-9.
101. Green SK, Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. *Anticancer Drug Des.* 1999 Apr;14(2):153-68.
102. Durand RE, Olive PL. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. *Methods Cell Biol.* 2001;64:211-33.
103. Gottesman MM, Ambudkar SV, Ni B, Aran JM, Sugimoto Y, Cardarelli CO, et al. Exploiting multidrug resistance to treat cancer. *Cold Spring Harb Symp Quant Biol.* 1994;59:677-83.
104. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. *Genome Res.* 2001 Jul;11(7):1156-66.
105. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annu Rev Pharmacol Toxicol.* 1999;39:361-98.

106. Gottesman MM. Mechanisms of cancer drug resistance. *Annu Rev Med.* 2002;53:615-27.
107. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer.* 2002 Jan;2(1):48-58.
108. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. *FEBS Lett.* 2006 May 22;580(12):2903-9.
109. Shen D, Pastan I, Gottesman MM. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. *Cancer Res.* 1998 Jan 15;58(2):268-75.
110. Shen DW, Goldenberg S, Pastan I, Gottesman MM. Decreased accumulation of [¹⁴C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. *J Cell Physiol.* 2000 Apr;183(1):108-16.
111. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. *Mol Pharmacol.* 1996 Feb;49(2):311-8.
112. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. *Nat Med.* 2001 May;7(5):584-90.
113. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. *Cell.* 1993 Sep 24;74(6):957-67.
114. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. *FASEB J.* 2001 Mar;15(3):719-30.
115. Rybarova S, Hajdukova M, Hodorova I, Kocisova M, Boor A, Brabencova E, et al. Expression of the multidrug resistance-associated protein 1 (MRP1) and

the lung resistance-related protein (LRP) in human lung cancer. *Neoplasma*. 2004;51(3):169-74.

116. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. *Clin Cancer Res*. 2001 Jun;7(6):1798-804.
117. Tanigawara Y. Role of P-glycoprotein in drug disposition. *Ther Drug Monit*. 2000 Feb;22(1):137-40.
118. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. *J Natl Cancer Inst*. 2000 Aug 16;92(16):1295-302.
119. Altan N, Chen Y, Schindler M, Simon SM. Defective acidification in human breast tumor cells and implications for chemotherapy. *J Exp Med*. 1998 May 18;187(10):1583-98.
120. Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A. Na⁺/H⁺ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. *Int J Cancer*. 2005 Jul 20;115(6):924-9.
121. Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. *Proc Natl Acad Sci U S A*. 1998 Aug 18;95(17):9831-6.
122. de Wet H, McIntosh DB, Conseil G, Baubichon-Cortay H, Krell T, Jault JM, et al. Sequence requirements of the ATP-binding site within the C-terminal nucleotide-binding domain of mouse P-glycoprotein: structure-activity

relationships for flavonoid binding. *Biochemistry*. 2001 Aug 28;40(34):10382-91.

123. Phang JM, Poore CM, Lopaczynska J, Yeh GC. Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells. *Cancer Res*. 1993 Dec 15;53(24):5977-81.

124. Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. *Biochem Pharmacol*. 1994 Oct 7;48(7):1437-45.

125. Dorward A, Sweet S, Moorehead R, Singh G. Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance. *J Bioenerg Biomembr*. 1997 Aug;29(4):385-92.

126. Jia L, Kelsey SM, Grahn MF, Jiang XR, Newland AC. Increased activity and sensitivity of mitochondrial respiratory enzymes to tumor necrosis factor alpha-mediated inhibition is associated with increased cytotoxicity in drug-resistant leukemic cell lines. *Blood*. 1996 Mar 15;87(6):2401-10.

127. Miccadei S, Fanciulli M, Bruno T, Paggi MG, Floridi A. Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells. *Oncol Res*. 1996;8(1):27-35.

128. Nieminen AL, Saylor AK, Herman B, Lemasters JJ. ATP depletion rather than mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition. *Am J Physiol*. 1994 Jul;267(1 Pt 1):C67-74.

129. Mankhetkorn S, Teodori E, Scapecchi S, Garnier-Suillerot A. Study of P-glycoprotein functionality in living resistant K562 cells after photolabeling with a verapamil analogue. *Biochem Pharmacol*. 1996 Jul 26;52(2):213-7.

130. Versantvoort CH, Withoff S, Broxterman HJ, Kuiper CM, Scheper RJ, Mulder NH, et al. Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. *Int J Cancer*. 1995 May 4;61(3):375-80.
131. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. *Exp Cell Res*. 2000 Apr 10;256(1):42-9.
132. Wang X. The expanding role of mitochondria in apoptosis. *Genes Dev*. 2001 Nov 15;15(22):2922-33.
133. Bernardi P, Scorrano L, Colonna R, Petronilli V, Di Lisa F. Mitochondria and cell death. Mechanistic aspects and methodological issues. *Eur J Biochem*. 1999 Sep;264(3):687-701.
134. Loeffler M, Kroemer G. The mitochondrion in cell death control: certainties and incognita. *Exp Cell Res*. 2000 Apr 10;256(1):19-26.
135. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. *Nature*. 2001 Jul 5;412(6842):95-9.
136. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. *Nature*. 1999 Feb 4;397(6718):441-6.
137. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell*. 2000 Jul 7;102(1):43-53.
138. Verhagen AM, Silke J, Ekert PG, Pakusch M, Kaufmann H, Connolly LM, et al. HtrA2 promotes cell death through its serine protease activity and its

- ability to antagonize inhibitor of apoptosis proteins. *J Biol Chem.* 2002 Jan 4;277(1):445-54.
- 139.Kroemer G, Reed JC. Mitochondrial control of cell death. *Nat Med.* 2000 May;6(5):513-9.
- 140.Bauer MK, Schubert A, Rocks O, Grimm S. Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis. *J Cell Biol.* 1999 Dec 27;147(7):1493-502.
- 141.Hayden MS, Ghosh S. Signaling to NF-kappaB. *Genes Dev.* 2004 Sep 15;18(18):2195-224.
- 142.Schmitz ML, Mattioli I, Buss H, Kracht M. NF-kappaB: a multifaceted transcription factor regulated at several levels. *Chembiochem.* 2004 Oct 4;5(10):1348-58.
- 143.Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. *Annu Rev Immunol.* 2000;18:621-63.
- 144.Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. *Science.* 2001 Aug 24;293(5534):1495-9.
- 145.Wei H, Saladi R, Lu Y, Wang Y, Palep SR, Moore J, et al. Isoflavone genistein: photoprotection and clinical implications in dermatology. *J Nutr.* 2003 Nov;133(11 Suppl 1):3811S-9S.
- 146.Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. *Trends Immunol.* 2004 Jun;25(6):280-8.
147. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways

- by diverse genetic abnormalities in multiple myeloma. *Cancer Cell*. 2007 Aug;12(2):115-30.
148. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell*. 2007 Aug;12(2):131-44.
149. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. *Oncogene*. 1999 Nov 22;18(49):6938-47.
150. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol*. 2005 Oct;5(10):749-59.
151. Baeuerle PA, Baichwal VR. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. *Adv Immunol*. 1997;65:111-37.
152. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. *Cancer Res*. 1999 Jul 15;59(14):3468-74.
153. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. *Oncogene*. 1999 Nov 22;18(49):6910-24.
154. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidert C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. *Oncogene*. 1999 Jan 28;18(4):943-53.
155. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. *Nat Rev Drug Discov*. 2009 Jan;8(1):33-40.
156. Surh YJ. Cancer chemoprevention with dietary phytochemicals. *Nat Rev Cancer*. 2003 Oct;3(10):768-80.

157. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe. *Clinical Cancer Research*. 2009 Jan 15;15(2):425-30.
158. Vanden Berghe W, Dijsselbloem N, Vermeulen L, Ndlovu N, Boone E, Haegeman G. Attenuation of mitogen- and stress-activated protein kinase-1-driven nuclear factor-kappaB gene expression by soy isoflavones does not require estrogenic activity. *Cancer Res*. 2006 May 1;66(9):4852-62.
159. Gong L, Li Y, Nedeljkovic-Kurepa A, Sarkar FH. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. *Oncogene*. 2003 Jul 24;22(30):4702-9.
160. Obolskiy D, Pischel I, Siriwatanametanon N, Heinrich M. *Garcinia mangostana* L.: a phytochemical and pharmacological review. *Phytother Res*. 2009 Jan 27.
161. Pinto MM, Sousa ME, Nascimento MS. Xanthone derivatives: new insights in biological activities. *Curr Med Chem*. 2005;12(21):2517-38.
162. Bracke ME, Vanhoecke BW, Derycke L, Bolca S, Possemiers S, Heyerick A, et al. Plant polyphenolics as anti-invasive cancer agents. *Anticancer Agents Med Chem*. 2008 Feb;8(2):171-85.
163. Kaileh M, Vanden Berghe W, Heyerick A, Horion J, Piette J, Libert C, et al. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. *J Biol Chem*. 2007 Feb 16;282(7):4253-64.
164. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. *Cancer Lett*. 2008 Oct 8;269(2):199-225.

165. Paul AT, Gohil VM, Bhutani KK. Modulating TNF-alpha signaling with natural products. *Drug Discov Today*. 2006 Aug;11(15-16):725-32.
166. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. *Nat Rev Cancer*. 2005 Apr;5(4):297-309.
167. Patel R, Krishnan R, Ramchandani A, Maru G. Polymeric black tea polyphenols inhibit mouse skin chemical carcinogenesis by decreasing cell proliferation. *Cell Prolif*. 2008 Jun;41(3):532-53.
168. Kundu JK, Hwang DM, Lee JC, Chang EJ, Shin YK, Fujii H, et al. Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets. *Cancer Lett*. 2009 Jan 8;273(1):86-97.
169. Dell'Eva R, Ambrosini C, Minghelli S, Noonan DM, Albini A, Ferrari N. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. *Carcinogenesis*. 2007 Feb;28(2):404-13.
170. Matsuda H, Yoshida K, Miyagawa K, Asao Y, Takayama S, Nakashima S, et al. Rotenoids and flavonoids with anti-invasion of HT1080, anti-proliferation of U937, and differentiation-inducing activity in HL-60 from *Erycibe expansa*. *Bioorg Med Chem*. 2007 Feb 1;15(3):1539-46.
171. Geeraerts B, Vanhoecke B, Vanden Berghe W, Philippe J, Offner F, Deforce D. Deguelin inhibits expression of IkappaBalpha protein and induces apoptosis of B-CLL cells in vitro. *Leukemia*. 2007 Aug;21(8):1610-8.
172. Beltz LA, Bayer DK, Moss AL, Simet IM. Mechanisms of cancer prevention by green and black tea polyphenols. *Anticancer Agents Med Chem*. 2006 Sep;6(5):389-406.

173. Terra X, Valls J, Vitrac X, Merrillon JM, Arola L, Ardevol A, et al. Grape-seed procyanidins act as antiinflammatory agents in endotoxin-stimulated RAW 264.7 macrophages by inhibiting NF κ B signaling pathway. *J Agric Food Chem.* 2007 May 30;55(11):4357-65.
174. Lin YL, Tsai SH, Lin-Shiau SY, Ho CT, Lin JK. Theaflavin-3,3'-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kappaB in macrophages. *Eur J Pharmacol.* 1999 Feb 19;367(2-3):379-88.
175. Hamalainen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. *Mediators Inflamm.* 2007;2007:45673.
176. Dijsselbloem N, Goriely S, Albarani V, Gerlo S, Francoz S, Marine JC, et al. A critical role for p53 in the control of NF-kappaB-dependent gene expression in TLR4-stimulated dendritic cells exposed to Genistein. *J Immunol.* 2007 Apr 15;178(8):5048-57.
177. Peng Q, Wei Z, Lau BH. Pycnogenol inhibits tumor necrosis factor-alpha-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. *Cell Mol Life Sci.* 2000 May;57(5):834-41.
178. Oak MH, Bedoui JE, Madeira SV, Chalupsky K, Schini-Kerth VB. Delphinidin and cyanidin inhibit PDGF(AB)-induced VEGF release in vascular smooth

muscle cells by preventing activation of p38 MAPK and JNK. *Br J Pharmacol.* 2006 Oct;149(3):283-90.

179. Corona G, Deiana M, Incani A, Vauzour D, Dessi MA, Spencer JP. Inhibition of p38/CREB phosphorylation and COX-2 expression by olive oil polyphenols underlies their anti-proliferative effects. *Biochem Biophys Res Commun.* 2007 Oct 26;362(3):606-11.

180. Tungjai M, Poompimon, W., Loetchutinat, C., Kothan, S., Dechsupa, N., Mankhetkorn, S. Spectrophotometric characterization of behavior and the predominant species of flavonoids in physiological buffer: determination of solubility, lipophilicity and anticancer efficacy. *The Open Drug Delivery Journal.* 2008;2:10-9.

181. Kaufman SJ, Foster RF. Replicating myoblasts express a muscle-specific phenotype. *Proc Natl Acad Sci U S A.* 1988 Dec;85(24):9606-10.

182. Stewart JD, Masi TL, Cumming AE, Molnar GM, Wentworth BM, Sampath K, et al. Characterization of proliferating human skeletal muscle-derived cells in vitro: differential modulation of myoblast markers by TGF-beta2. *J Cell Physiol.* 2003 Jul;196(1):70-8.

183. Dechsupa N, Mankhetkorn, S. . P-Glycoprotein-Mediated Efflux and Drug Sequestration in Lysosomes Confer Advantages of K562 Multidrug Resistance Sublines to Survive Prolonged Exposure to Cytotoxic Agents. *American Journal of Applied Sciences.* 2009;6:1637-46.

184. Pourahmad J, Ross S, O'Brien PJ. Lysosomal involvement in hepatocyte cytotoxicity induced by Cu(2+) but not Cd(2+). *Free Radic Biol Med.* 2001 Jan 1;30(1):89-97.

- 185.Laochariyakul P, Ponglikitmongkol M, Mankhetkorn S. Functional study of intracellular P-gp- and MRP1-mediated pumping of free cytosolic pirarubicin into acidic organelles in intrinsic resistant SiHa cells. *Can J Physiol Pharmacol.* 2003 Aug;81(8):790-9.
- 186.Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. *J Biol Chem.* 1998 Feb 6;273(6):3285-90.
- 187.Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. *J Biol Chem.* 1999 Nov 5;274(45):32091-8.
- 188.Plaisance S, Vanden Berghe W, Boone E, Fiers W, Haegeman G. Recombination signal sequence binding protein Jkappa is constitutively bound to the NF-kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. *Mol Cell Biol.* 1997 Jul;17(7):3733-43.
- 189.Vanden Berghe T, Denecker G, Brouckaert G, Vadimovich Krysko D, D'Herde K, Vandenabeele P. More than one way to die: methods to determine TNF-induced apoptosis and necrosis. *Methods Mol Med.* 2004;98:101-26.
- 190.Denecker G, Vercaemmen D, Steemans M, Vanden Berghe T, Brouckaert G, Van Loo G, et al. Death receptor-induced apoptotic and necrotic cell death: differential role of caspases and mitochondria. *Cell Death Differ.* 2001 Aug;8(8):829-40.


191. Vanden Berghe T, Kalai M, van Loo G, Declercq W, Vandenabeele P. Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis. *J Biol Chem*. 2003 Feb 21;278(8):5622-9.
192. Hecht SS, Huang C, Stoner GD, Li J, Kenney PM, Sturla SJ, et al. Identification of cyanidin glycosides as constituents of freeze-dried black raspberries which inhibit anti-benzo[a]pyrene-7,8-diol-9,10-epoxide induced NFkappaB and AP-1 activity. *Carcinogenesis*. 2006 Aug;27(8):1617-26.
193. Pang Y, Peel GJ, Sharma SB, Tang Y, Dixon RA. A transcript profiling approach reveals an epicatechin-specific glucosyltransferase expressed in the seed coat of *Medicago truncatula*. *Proc Natl Acad Sci U S A*. 2008 Sep 16;105(37):14210-5.
194. Bednarski BK, Ding X, Coombe K, Baldwin AS, Kim HJ. Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. *Mol Cancer Ther*. 2008 Jul;7(7):1827-35.
195. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. *Trends Biochem Sci*. 2005 Jan;30(1):43-52.
196. Natoli G, Saccani S, Bosisio D, Marazzi I. Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time. *Nat Immunol*. 2005 May;6(5):439-45.
197. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. *Curr Opin Cell Biol*. 2009 Apr;21(2):317-24.
198. Daschner PJ, Ciolino HP, Plouzek CA, Yeh GC. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. *Breast Cancer Res Treat*. 1999 Feb;53(3):229-40.

199. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. *Carcinogenesis*. 2008 Jun;29(6):1235-43.
200. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A. Control of multidrug resistance gene *mdr1* and cancer resistance to chemotherapy by the longevity gene *sirt1*. *Cancer Res*. 2005 Nov 15;65(22):10183-7.
201. Gangadharan C, Thoh M, Manna SK. Inhibition of constitutive activity of nuclear transcription factor κ B sensitizes doxorubicin-resistant cells to apoptosis. *J Cell Biochem*. 2009 May 15;107(2):203-13.
202. Huang HC, Nguyen T, Pickett CB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. *Proc Natl Acad Sci U S A*. 2000 Nov 7;97(23):12475-80.
203. Vanden Berghe W, Ndlovu MN, Hoya-Arias R, Dijsselbloem N, Gerlo S, Haegeman G. Keeping up NF- κ B appearances: epigenetic control of immunity or inflammation-triggered epigenetics. *Biochem Pharmacol*. 2006 Oct 30;72(9):1114-31.
204. Dong J, Jimi E, Zhong H, Hayden MS, Ghosh S. Repression of gene expression by unphosphorylated NF- κ B p65 through epigenetic mechanisms. *Genes Dev*. 2008 May 1;22(9):1159-73.
205. Nowak DE, Tian B, Jamaluddin M, Boldogh I, Vergara LA, Choudhary S, et al. RelA Ser276 phosphorylation is required for activation of a subset of NF- κ B-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. *Mol Cell Biol*. 2008 Jun;28(11):3623-38.

206. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. *Cell Death Differ.* 2009 Apr 17.
207. Formica JV, Regelson W. Review of the biology of Quercetin and related bioflavonoids. *Food Chem Toxicol.* 1995 Dec;33(12):1061-80.
208. Hollman PC, Katan MB. Absorption, metabolism and health effects of dietary flavonoids in man. *Biomed Pharmacother.* 1997;51(8):305-10.
209. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. *Oncogene.* 2003 Jan 9;22(1):90-7.
210. Thevenod F, Friedmann JM, Katsen AD, Hauser IA. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. *J Biol Chem.* 2000 Jan 21;275(3):1887-96.
211. Kunsch C, Rosen CA. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. *Mol Cell Biol.* 1993 Oct;13(10):6137-46.
212. Benayoun BA, Veitia RA. A post-translational modification code for transcription factors: sorting through a sea of signals. *Trends Cell Biol.* 2009 May;19(5):189-97.
213. Jacques E, Tchenio T, Piton G, Romeo PH, Baud V. RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. *Proc Natl Acad Sci U S A.* 2005 Oct 11;102(41):14635-40.
214. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C. A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. *Trends Biochem Sci.* 2008 Jul;33(7):339-49.

215. Natoli G. When sirtuins and NF-kappaB collide. *Cell*. 2009 Jan 9;136(1):19-21.
216. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. *Mol Cell*. 2002 Mar;9(3):625-36.
217. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. *Nat Rev Cancer*. 2003 Nov;3(11):859-68.
218. Gangadharan C, Thoh M, Manna SK. Late phase activation of nuclear transcription factor kappaB by doxorubicin is mediated by interleukin-8 and induction of apoptosis via FasL. *Breast Cancer Res Treat*. 2009 Aug 2.
219. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. *Cell Death Differ*. 2002 Nov;9(11):1266-72.
220. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. *Proc Natl Acad Sci U S A*. 1998 Jun 9;95(12):7024-9.
221. Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, et al. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. *Oncogene*. 2001 May 17;20(22):2749-60.
222. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. *Blood*. 1999 Feb 1;93(3):1075-85.

223.Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. *Blood*. 2000 Apr 1;95(7):2378-85.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved